Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2181308 plus docetaxel versus docetaxel in previously treated advanced non-small cell lung cancer
2009-017591-24Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing LY2181308 plus docetaxel with Docetaxel alone (2 arms). Primary endpoint: Change in tumor size. Started Jan 2010; status: completed.
02
Drugs
gataparsendocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-017591-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017591-24.